Do current therapies target kidney inflammation?
At Sygnature Discovery, we specialise in the testing of anti-inflammatory therapies in our validated ex vivo and in vivo models.
Inflammation in the diseased kidney not only leads to progressive loss of kidney function but also contributes to the development of cardiovascular complications, increasing the risk of heart disease. However, there is a limited number of therapies available to target this specific aspect.
While current therapies may slow down the progression of kidney disease, they do not effectively counteract the underlying triggers. It is important to raise awareness that anti-inflammatory therapeutics hold promise as our primary line of defence against kidney disease.